Skip to content
Visnia
CtrlK
EconomyAI buildoutMarket MapFundsWatchlist
Log in
Market cap
Revenue
Net income
Cash on hand
Gross margin
Net margin
EPS
P/E ratio
Search
Market mapFundsWatchlist
Visnia

DStarling Oncology, Inc.

EconomyAI buildoutMarket MapFundsWatchlist
Log in
D

Starling Oncology, Inc.

$2.01Close · Dec 11, 2025
  • Overview
  • Financial statements
  • Metrics
  • Quarterly earnings
  • Burn Rate
  • Similar companies
  • Insider Transactions
Loading financials
Income statement waterfall. Revenue $161.28M. Net result −$9.79M. A thin axis line marks the loss-zone boundary.

Income statement waterfall. Green diagonal stripes add to the running result, red diagonal stripes subtract from it, and a thin axis line marks the loss-zone boundary.

  • Revenue: $161.28M. Running result $161.28M. Capitated Revenue: $27.97M. Clinical Research Trials And Other Revenue: $3.85M. Fee For Service: $30.85M. Health Care Specialty Pharmacy: $98.61M.
  • Cost of revenue: $0. Running result $161.28M.
  • Gross profit: $161.28M. Running result $161.28M.
  • Operating costs: −$165.9M. Running result −$4.62M.
  • Operating income: −$4.62M. Running result −$4.62M.
  • Other expense: −$5.17M. Running result −$9.79M.
  • Pre-tax loss: −$9.79M. Running result −$9.79M.
  • Income tax benefit: $0. Running result −$9.79M.
  • Net loss: −$9.79M. Running result −$9.79M.